13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001825034
Total reported value
$439.8M
$439.8M
11 檔
51.5%
During the Q3 2025 filing period, Euclidean Capital LLC (CIK: 0001825034) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $439.8M across 11 reported positions.
Euclidean Capital LLC executed strategic sector rebalancing during Q3 2025, establishing 1 new positions while fully exiting 1 holdings and trimming 1 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VEU | Vanguard Ftse All-world Ex-u | ETF-Other | 77.31% | -0.33% | +20.32% | |
| 2 | INDA | Ishares Msci India ETF | ETF-Other | 8.08% | -0.26% | -84.76% | |
| 3 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 4.99% | -0.76% | — | |
| 4 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 3.23% | -0.17% | — | |
| 5 | ALEC | Alector Inc | Stock-Other | 1.63% | -0.12% | — | |
| 6 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 1.55% | -0.03% | — | |
| 7 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 1.15% | — | — | |
| 8 | RAPT | Rapt Therapeutics Inc | Stock-Other | 0.89% | — | — | |
| 9 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.69% | -0.01% | — | |
| 10 | SRZN | Surrozen Inc | Stock-Other | 0.47% | -0.13% | — | |
| 11 | SRZNW | Surrozen Inc-cw25 | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VEU | Vanguard Ftse All-world Ex-u | +31.9% | +20.32% | Add |
| 2 | ORIC | Oric Pharmaceuticals Inc | +2.9% | — | Unchanged |
| 3 | FHTX | Foghorn Therapeutics Inc | +1.1% | — | Unchanged |
| 4 | ALEC | Alector Inc | +1% | — | Unchanged |
| 5 | TNYA | Tenaya Therapeutics Inc | +0.5% | — | Unchanged |
| 6 | PMVP | Pmv Pharmaceuticals Inc | +0.5% | — | Unchanged |
| 7 | SPY | Ss Spdr S&p 500 ETF Trust-us | +0.3% | — | Unchanged |
| 8 | SRZN | Surrozen Inc | +0.1% | — | Unchanged |
| 9 | SRZNW | Surrozen Inc-cw25 | — | — | Unchanged |
| 10 | INDA | Ishares Msci India ETF | -38.8% | -84.76% | Trim |
| 11 | RAPT | Rapt Therapeutics Inc | — | NEW | New buy |
| 12 | ✓ | Rapt Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Euclidean Capital LLC reported a total U.S. public equity portfolio value of $439.8M across 11 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including VEU, INDA, ORIC) accounted for 51.5% of total reported equity market value during Q3 2025.
Top New Position Initiated
RAPT
市值: $2.1M
Top Position Liquidated / Trimmed
RAPT THERAPEUTICS INC
前期市值: $802.6K
During Q3 2025, Euclidean Capital LLC's top holdings by market value included VEU (77.3%)、INDA (8.1%)、ORIC (5.0%). The largest single position, VEU, represented 77.3% of total portfolio value.
In Q3 2025, Euclidean Capital LLC made 4 total portfolio adjustments, initiating 1 new buys, adding to 1 positions, trimming 1 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.